Bone Density Conservation Agents

Agents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.

Also Known As:

Networked: 313 relevant articles (16 outcomes, 30 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Bilezikian, John P: 9 articles (09/2011 - 03/2002)
2.	Cosman, Felicia: 5 articles (11/2010 - 12/2005)
3.	Ohta, Hiroaki: 4 articles (12/2015 - 04/2005)
4.	Lewiecki, E Michael: 4 articles (08/2015 - 04/2009)
5.	Vestergaard, Peter: 4 articles (12/2011 - 02/2005)
6.	Shiraki, Masataka: 3 articles (12/2015 - 11/2007)
7.	Bedogni, Alberto: 3 articles (01/2015 - 02/2014)
8.	Campisi, Giuseppina: 3 articles (01/2015 - 02/2014)
9.	Di Fede, Olga: 3 articles (01/2015 - 02/2014)
10.	Fedele, Stefano: 3 articles (01/2015 - 02/2014)

Related Diseases

1.	Osteoporosis 01/01/2001 - "Because of its bone anabolic action, PTH is expected to be effective for osteoporosis in those of advanced age with suppressed bone remodelling, which might not respond favourably to antiresorptive agents." 06/01/1998 - "Several studies indicate that screening for these bone markers may be useful for improving the prognostic assessment of postmenopausal women in combination with bone mass measurement, that is, their risk for osteoporosis and, ultimately, for fractures and to monitor rapidly the efficacy of antiresorptive drugs." 05/01/2010 - "Consequently, the present review aims to analyze the scientific evidence on the diagnosis and treatment of osteoporosis, and particularly the evidence on the antifracture efficacy of distinct antiresorptive agents and anabolic drugs in people older than 75 years." 10/01/2013 - "In clinical trials of patients with osteoporosis, inhibition of RANK-L has reduced bone loss and damage to the microarchitecture and was associated with an increase in mass and resistance at different skeletal sites, with most significant effects than those demonstrated by any other antiresorptive drugs. " 01/01/2012 - "In Vivo Study on the Pharmacological Interactions between a Chinese Herbal Formula ELP and Antiresorptive Drugs to Counteract Osteoporosis."
2.	Postmenopausal Osteoporosis 01/01/2005 - "Antiresorptive agents are effective in preventing and treating postmenopausal osteoporosis, provided they are taken as directed. " 10/01/2012 - "A total of 565 postmenopausal osteoporosis who were treated antiresorptive drugs were included in this prospective observational study. " 08/01/2008 - "The incidence of ICR during treatment with antiresorptive agents among patients with severe postmenopausal osteoporosis in a routine setting is considerably higher than that observed in randomized clinical trials." 11/01/2015 - "Mixed Treatment Comparison to Rank Antiresorptive Agents In Preventing New Non Vertebral Fractures In Postmenopausal Osteoporosis." 04/01/2015 - "Oral antiresorptive agents are considered as the standard of care for the prevention and treatment of women with postmenopausal osteoporosis. "
3.	Neoplasms (Cancer) 01/01/2015 - "In patients with cancer-treatment induced bone loss (CTIBL), antiresorptive agents have been shown to improve bone mineral density (BMD) and to reduce the risk of fractures. " 10/01/2012 - "This review summarises the current data on the course of cancer in clinical trials of the antiresorptive agents and provides important insight into the relative anticancer potential of the various therapies." 01/01/2014 - "Our recent observations indicated that a decline in the ability of the immune cells to recognize and kill the tumor drives tumor dissemination to bone even when osteoclasts are inhibited by potent antiresorptive agents. " 07/01/2012 - "An appreciation for the high incidence of SRE in other advanced cancers involving the bone has led to the approval of potent antiresorptive agents because they delay the time to the first SRE and decrease the incidence of SRE. " 01/01/2008 - "Novel antiresorptive agents targeting receptor activator of nuclear factor κB ligand have great potential in skeletal protection and prevention of bone loss related to cancer therapy. "
4.	Neoplasm Metastasis (Metastasis) 01/01/2015 - "Currently, the use of antiresorptive drugs to prevent bone metastases still remains a field of controversies and further trials are needed to identify patient subgroups that may profit from early therapy. " 02/01/2013 - "Future clinical trials of IAP antagonist-based therapy may require detailed examination of this potential for enhanced bone metastasis and osteoporosis, as well as possible combination with antiresorptive agents." 01/01/2015 - "Bone antiresorptive agents in the treatment of bone metastases associated with solid tumours or multiple myeloma." 07/01/2012 - "The risk and rate of SRE after diagnosis of bone metastasis have not been described in thyroid cancer; antiresorptive agents are not routinely used. " 07/01/2006 - "Bisphosphonate antiresorptive drugs are the approved treatment for solid tumor bone metastases. "
5.	Back Pain (Backache) 01/01/2006 - "Teriparatide [rhPTH (1-34)] reduces fracture risk, and in a published meta-analysis of clinical trials, teriparatide-treated patients had reduced incidence of back pain relative to placebo or to antiresorptive drugs. "

Related Drugs and Biologics

1.	Diphosphonates
2.	Teriparatide (Parathar)
3.	Alendronate (Alendronate Sodium)
4.	risedronic acid (risedronate)
5.	Etidronic Acid (HEDP)
6.	Hormones
7.	Calcium
8.	Vitamin D
9.	Radiopharmaceuticals
10.	Proton Pumps (Proton Pump)

Related Therapies and Procedures

1.	Hormone Replacement Therapy (Therapy, Hormone Replacement)
2.	Transplantation (Transplant Recipients)
3.	Kidney Transplantation
4.	Vertebroplasty
5.	Resistance Training